Tonix Pharmaceuticals Holding Corp. TNXP

I hate to say this: From CHAT GPT:

I checked the filings for Tonix Pharmaceuticals Holding Corp. (TNXP) and found the following with respect to the reverse stock split authorization:
• The company filed a notice of annual meeting for May 8, 2025 that included a proposal to authorize the board to effect one or more reverse stock splits of the common stock, with an aggregate ratio of not less than 1-for-2 and not greater than 1-for-250. 
• A news summary from TipRanks says that at that meeting the shareholders approved this proposal (among other proposals). 

So in short: yes — the shareholder authorization was approved at the meeting on May 8, 2025, which gives the board discretion to implement a reverse stock split (within that 1:2 to 1:250 range) within one year of approval.

Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Tonix Pharma (TNXP – Research Report) today and set a price target of $70.00.

Investor sentiment was also boosted Thursday after CEO Seth Lederman disclosed the purchase of 4,000 shares of company stock for $86,200.

FDA PDUFA goal date of August 15, 2025, for TNX-102 SL, which could become the first new drug for treating fibromyalgia in over 15 years, highlighting a significant advancement in treatment options for patients.

My point is…..there is no dilution in the near future

Cash Position (Millions)
The company has 25.5 months of cash left based on quarterly cash burn of -$15.23M and estimated current cash of $129.5M.

$TNXP God knows where TNXP IS going to go $400, 500 or thousand.
Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia
Tonix Pharmaceuticals Holding Corp.
March 24, 2025 08:00 ET
On track for August 15, 2025 FDA PDUFA goal date

TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years

Commercial planning for TNX-102 SL underway for launch in the fourth quarter of 2025

CHATHAM, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the U.S. Food and Drug Administration (FDA) will not require an Advisory Committee meeting to discuss the Company’s New Drug Application (NDA) for TNX-102 SL for the management of fibromyalgia. If approved, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) would be the first new treatment option for fibromyalgia patients in 15 years.

“We are pleased that FDA will not require an advisory committee meeting as part of the regulatory review process for TNX-102 SL,” said Seth Lederman, M.D., President, and Chief Executive Officer of Tonix Pharmaceuticals. “We believe that TNX-102 SL has the potential to be the first member of a new class of medicines for the management of fibromyalgia, a debilitating condition affecting over 10 million adults in the U.S. We believe we are well positioned to launch TNX-102 SL for the management of fibromyalgia in the fourth quarter of 2025 if approved by the FDA.”

Why did this ? go down?

$19 ??????

TNXP ??